Nico Gagelmann
@nicogagelmann.bsky.social
Hematologist. Academic. Train. Think. Let's create and integral and loving actuality.
Pinned
Nico Gagelmann
@nicogagelmann.bsky.social
· Oct 12
Finally in Boston!
Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social.
A place of science, purpose and hope.
Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social.
A place of science, purpose and hope.
Finally in Boston!
Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social.
A place of science, purpose and hope.
Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social.
A place of science, purpose and hope.
October 12, 2025 at 11:45 AM
Finally in Boston!
Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social.
A place of science, purpose and hope.
Honored to join @danafarber.bsky.social, eager to learn and contribute in this terrific community @coleman-lindsley.bsky.social.
A place of science, purpose and hope.
Thank you all who made COSTEM 2025 THE event for transplant & cellular therapies❗️
Faculty who fight REAL debates
Audience that ask REAL questions
Unity amid controversy🙏
See you 1-3 October 2026 in Berlin again!
Faculty who fight REAL debates
Audience that ask REAL questions
Unity amid controversy🙏
See you 1-3 October 2026 in Berlin again!
September 29, 2025 at 6:16 AM
Thank you all who made COSTEM 2025 THE event for transplant & cellular therapies❗️
Faculty who fight REAL debates
Audience that ask REAL questions
Unity amid controversy🙏
See you 1-3 October 2026 in Berlin again!
Faculty who fight REAL debates
Audience that ask REAL questions
Unity amid controversy🙏
See you 1-3 October 2026 in Berlin again!
Last Call for Early Bird Registration
Join us at the 10th COSTEM Congress!
🗓️ September 25–28, 2025
📍 Berlin, Germany
Don't miss your chance to save – Early Bird registration closes July 31st!
costem.cme-congresses.com/registration/
Join us at the 10th COSTEM Congress!
🗓️ September 25–28, 2025
📍 Berlin, Germany
Don't miss your chance to save – Early Bird registration closes July 31st!
costem.cme-congresses.com/registration/
Registration - COSTEM Congress 2025
Registration for COSTEM 2025
costem.cme-congresses.com
July 28, 2025 at 8:20 AM
Last Call for Early Bird Registration
Join us at the 10th COSTEM Congress!
🗓️ September 25–28, 2025
📍 Berlin, Germany
Don't miss your chance to save – Early Bird registration closes July 31st!
costem.cme-congresses.com/registration/
Join us at the 10th COSTEM Congress!
🗓️ September 25–28, 2025
📍 Berlin, Germany
Don't miss your chance to save – Early Bird registration closes July 31st!
costem.cme-congresses.com/registration/
Reposted by Nico Gagelmann
🎥 Check out our recent interview from #CART25 with @nicogagelmann.bsky.social, in which he highlights the need to address inequality & inequity in access to #CARTCell therapy across Europe:
👉 buff.ly/4gBhWeD
#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky
👉 buff.ly/4gBhWeD
#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky
February 18, 2025 at 3:54 PM
🎥 Check out our recent interview from #CART25 with @nicogagelmann.bsky.social, in which he highlights the need to address inequality & inequity in access to #CARTCell therapy across Europe:
👉 buff.ly/4gBhWeD
#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky
👉 buff.ly/4gBhWeD
#ImmunoOnc #HemOnc #Hematology #MedSky #BloodSky #HemeSky
Reposted by Nico Gagelmann
Out now in Blood Advances 🙌🏽
Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation!
Also read this excellent commentary by my good friend @nicogagelmann.bsky.social 👇🏽
ashpublications.org/bloodadvance...
Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation!
Also read this excellent commentary by my good friend @nicogagelmann.bsky.social 👇🏽
ashpublications.org/bloodadvance...
February 12, 2025 at 4:41 AM
Out now in Blood Advances 🙌🏽
Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation!
Also read this excellent commentary by my good friend @nicogagelmann.bsky.social 👇🏽
ashpublications.org/bloodadvance...
Our work from Princess Margaret Cancer Centre evaluating the role of PTCy in matched sibling donor allogeneic transplantation!
Also read this excellent commentary by my good friend @nicogagelmann.bsky.social 👇🏽
ashpublications.org/bloodadvance...
Let's learn hematology in 2025🩸
Day 27: hemophilia characteristics
Day 27: hemophilia characteristics
January 27, 2025 at 1:40 PM
Let's learn hematology in 2025🩸
Day 27: hemophilia characteristics
Day 27: hemophilia characteristics
🎉Finally published🎉
Cilta-cel vs ide-cel for relapsed or refractory multiple myeloma
@hemasphere-journal.bsky.social
onlinelibrary.wiley.com/doi/full/10....
Cilta-cel vs ide-cel for relapsed or refractory multiple myeloma
@hemasphere-journal.bsky.social
onlinelibrary.wiley.com/doi/full/10....
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Levera...
onlinelibrary.wiley.com
January 19, 2025 at 6:57 PM
🎉Finally published🎉
Cilta-cel vs ide-cel for relapsed or refractory multiple myeloma
@hemasphere-journal.bsky.social
onlinelibrary.wiley.com/doi/full/10....
Cilta-cel vs ide-cel for relapsed or refractory multiple myeloma
@hemasphere-journal.bsky.social
onlinelibrary.wiley.com/doi/full/10....
Reposted by Nico Gagelmann
🎉Finally published🎉
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment
for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease,
but the role of mutation cl...
www.nejm.org
January 9, 2025 at 11:05 AM
🎉Finally published🎉
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
Reposted by Nico Gagelmann
In a single-group, single-center study, clearance of driver mutations 30 days after bone marrow transplantation predicted long-term disease-free survival in patients with myelofibrosis. Read the full study results: nej.md/4fQNdKn
#MedSky
#MedSky
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment
for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease,
but the role of mutation cl...
nej.md
January 10, 2025 at 2:12 PM
In a single-group, single-center study, clearance of driver mutations 30 days after bone marrow transplantation predicted long-term disease-free survival in patients with myelofibrosis. Read the full study results: nej.md/4fQNdKn
#MedSky
#MedSky
Reposted by Nico Gagelmann
Reposted by Nico Gagelmann
Reposted by Nico Gagelmann
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
January 9, 2025 at 2:14 PM
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
Reposted by Nico Gagelmann
a blockbuster paper by @nicogagelmann.bsky.social et al in @nejm.org on the impact of driver mutation clearance in patients with MF that underwent allo-HCT!
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
January 9, 2025 at 1:06 AM
a blockbuster paper by @nicogagelmann.bsky.social et al in @nejm.org on the impact of driver mutation clearance in patients with MF that underwent allo-HCT!
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
🎉Finally published🎉
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
Clearance of Driver Mutations after Transplantation for Myelofibrosis | NEJM
Allogeneic hematopoietic stem-cell transplantation is the only curative treatment
for myelofibrosis. Driver mutations are the pathophysiological hallmark of the disease,
but the role of mutation cl...
www.nejm.org
January 9, 2025 at 11:05 AM
🎉Finally published🎉
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
Clearance of driver mutations after transplantation for myelofibrosis
@nejm.org
www.nejm.org/doi/full/10....
Reposted by Nico Gagelmann
December 11, 2024 at 6:33 PM
Reposted by Nico Gagelmann
December 10, 2024 at 8:43 PM
What a wonderful #ASH24
Honored to receive @ash-hematology.bsky.social Abstract Achievement Award, meet friends, celebrate colleagues' achievements, enjoy terrific science and San Diego.
Until next year 🙏🩸❤️
Honored to receive @ash-hematology.bsky.social Abstract Achievement Award, meet friends, celebrate colleagues' achievements, enjoy terrific science and San Diego.
Until next year 🙏🩸❤️
December 10, 2024 at 6:40 PM
What a wonderful #ASH24
Honored to receive @ash-hematology.bsky.social Abstract Achievement Award, meet friends, celebrate colleagues' achievements, enjoy terrific science and San Diego.
Until next year 🙏🩸❤️
Honored to receive @ash-hematology.bsky.social Abstract Achievement Award, meet friends, celebrate colleagues' achievements, enjoy terrific science and San Diego.
Until next year 🙏🩸❤️
Reposted by Nico Gagelmann
Tomorrow @nicogagelmann.bsky.social will take over our Twitter account, bringing you live updates & expert takes straight from #ASH24 🗞️🩸📱
Give us a follow over there so you don't miss the action 👉 x.com/VJHemOnc 👀
Give us a follow over there so you don't miss the action 👉 x.com/VJHemOnc 👀
December 7, 2024 at 5:45 PM
Tomorrow @nicogagelmann.bsky.social will take over our Twitter account, bringing you live updates & expert takes straight from #ASH24 🗞️🩸📱
Give us a follow over there so you don't miss the action 👉 x.com/VJHemOnc 👀
Give us a follow over there so you don't miss the action 👉 x.com/VJHemOnc 👀
Reposted by Nico Gagelmann
Now @nicogagelmann.bsky.social on molecular genetics and JAKi impact on allo-HCT in MF
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit
December 7, 2024 at 11:03 PM
Now @nicogagelmann.bsky.social on molecular genetics and JAKi impact on allo-HCT in MF
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit
🎉Finally out and timely for #ASH24 @ash-hematology.bsky.social 🎉
Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm
t.co/F7QjOoavKO
Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm
t.co/F7QjOoavKO
https://www.nature.com/articles/s41408-024-01197-2
t.co
December 6, 2024 at 12:45 AM
🎉Finally out and timely for #ASH24 @ash-hematology.bsky.social 🎉
Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm
t.co/F7QjOoavKO
Happy to share our international work suggesting bispecific antibodies as standard of care for relapse after CAR-T in multiple #myeloma #mmsm
t.co/F7QjOoavKO
Happy to present first European comparison of cilta-cel vs ide-cel for #myeloma #ASH24:
-Cilta-cel with better ORR, CR, PFS
-Similar NRM
-Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel
👉associated with response and with ICANS for cilta-cel
@ash-hematology.bsky.social
-Cilta-cel with better ORR, CR, PFS
-Similar NRM
-Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel
👉associated with response and with ICANS for cilta-cel
@ash-hematology.bsky.social
December 4, 2024 at 9:17 AM
Happy to present first European comparison of cilta-cel vs ide-cel for #myeloma #ASH24:
-Cilta-cel with better ORR, CR, PFS
-Similar NRM
-Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel
👉associated with response and with ICANS for cilta-cel
@ash-hematology.bsky.social
-Cilta-cel with better ORR, CR, PFS
-Similar NRM
-Peak CAR-T expansion day 14 for cilta-cel vs day 7 for ide-cel
👉associated with response and with ICANS for cilta-cel
@ash-hematology.bsky.social
Reposted by Nico Gagelmann
Honored to be featured on the @ash-hematology.bsky.social ASH News Daily #ASH24 follow list! I'll be posting on both my Twitter (https://buff.ly/3Zy7BLc) and BS (https://buff.ly/3B9SpKU), so please do follow! https://buff.ly/49iWb1d
December 2, 2024 at 4:16 PM
Honored to be featured on the @ash-hematology.bsky.social ASH News Daily #ASH24 follow list! I'll be posting on both my Twitter (https://buff.ly/3Zy7BLc) and BS (https://buff.ly/3B9SpKU), so please do follow! https://buff.ly/49iWb1d
Reposted by Nico Gagelmann
#ASH24 of the day:
Talquetamab Bridging before CAR-T
-Talq bridging: 62% ORR (14% CR)
-Post-CAR-T: 97.5% ORR (35% CR)
-Safety: Mild toxicities during talq (no grade ≥3 CRS, 2.5% ICANS)
-Post-CAR-T: less CRS (65%), ICANS (2% grade 3)
Should be standard of care #mmsm @ash-hematology.bsky.social
Talquetamab Bridging before CAR-T
-Talq bridging: 62% ORR (14% CR)
-Post-CAR-T: 97.5% ORR (35% CR)
-Safety: Mild toxicities during talq (no grade ≥3 CRS, 2.5% ICANS)
-Post-CAR-T: less CRS (65%), ICANS (2% grade 3)
Should be standard of care #mmsm @ash-hematology.bsky.social
December 1, 2024 at 7:21 PM
#ASH24 of the day:
Talquetamab Bridging before CAR-T
-Talq bridging: 62% ORR (14% CR)
-Post-CAR-T: 97.5% ORR (35% CR)
-Safety: Mild toxicities during talq (no grade ≥3 CRS, 2.5% ICANS)
-Post-CAR-T: less CRS (65%), ICANS (2% grade 3)
Should be standard of care #mmsm @ash-hematology.bsky.social
Talquetamab Bridging before CAR-T
-Talq bridging: 62% ORR (14% CR)
-Post-CAR-T: 97.5% ORR (35% CR)
-Safety: Mild toxicities during talq (no grade ≥3 CRS, 2.5% ICANS)
-Post-CAR-T: less CRS (65%), ICANS (2% grade 3)
Should be standard of care #mmsm @ash-hematology.bsky.social